BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21224677)

  • 1. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
    Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
    Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
    Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib for advanced hepatocellular carcinoma: a systematic review.
    Ling-lin Z; Li M; Jin-hui T; Ke-hu Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):51-7. PubMed ID: 21375938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
    Welker MW; Lubomierski N; Gog C; Herrmann E; Engels K; Vogl TJ; Bechstein WO; Zeuzem S; Trojan J
    J Chemother; 2010 Jun; 22(3):205-11. PubMed ID: 20566428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
    Di Costanzo GG; Tortora R; Iodice L; Lanza AG; Lampasi F; Tartaglione MT; Picciotto FP; Mattera S; De Luca M
    Dig Liver Dis; 2012 Sep; 44(9):788-92. PubMed ID: 22579445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
    Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
    Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
    Zhang L; Ren ZG; Gan YH; Wang YH; Zhang BH; Chen Y; Xie XY; Ge NL; Ye SL
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):630-3. PubMed ID: 21122420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
    Dufour JF; Hoppe H; Heim MH; Helbling B; Maurhofer O; Szucs-Farkas Z; Kickuth R; Borner M; Candinas D; Saar B
    Oncologist; 2010; 15(11):1198-204. PubMed ID: 21036880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive squamous cell carcinoma and sorafenib in a black patient.
    Donaldson MR; Stetson CL; Smith JL
    Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.